2-(3,4-二甲基苯基氨基甲酰基)安息香酸 | 17332-48-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3,4-二甲基苯基氨基甲酰基)安息香酸
• 英文名称: 2-[(3,4-Dimethylphenyl)carbamoyl]benzoic acid
• CAS: 17332-48-8
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.29
• InChiKey: DBKSCNINEZDXAU-UHFFFAOYSA-N

物化性质

• 沸点：
  388.5±42.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  苯酐 、 3,4-二甲基苯胺 生成 2-(3,4-二甲基苯基氨基甲酰基)安息香酸
  参考文献：
  名称：

  CERMAK, JIRI;SEBRANEK, MILOSLAV;NYVLTOVA, ZORA;JIRMAN, JOSEF, COLLECT. CZECHOSL. CHEM. COMMUN., 56,(1991) N, C. 809-821

  摘要：

  DOI：

文献信息

• Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
  申请人：Mackerell Alexander

  公开号：US20070099970A1

  公开（公告）日：2007-05-03

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
  申请人：Mackerell Alexander

  公开号：US20070196395A1

  公开（公告）日：2007-08-23

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
  申请人：Neckers Leonard M.

  公开号：US20120283215A1

  公开（公告）日：2012-11-08

  Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
• COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER
  申请人：University of Maryland, Baltimore

  公开号：US20150313898A1

  公开（公告）日：2015-11-05

  Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.
• FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS
  申请人：THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

  公开号：US20160030369A1

  公开（公告）日：2016-02-04

  Liposomes comprising an FKBP52 targeting agent (FTA) are disclosed. Pharmaceutical compositions comprising an FTA, a solvent, and a surfactant are disclosed. Pharmaceutical compositions comprising a cyclodextrin and/or a derivative thereof and an FTA are also disclosed. Method of detecting one or more compounds in a sample by liquid chromatography/tandem mass spectrometry (LC/MS/MS), methods of treating or preventing cancer, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostatitis, enlarged prostate, or insulin-independent diabetes, and methods of inhibiting spermatogenesis or fertilized oocyte implantation in a mammal are also provided.